Generate Biomedicines (NASDAQ:GENB) Stock Crosses Above Two Hundred Day Moving Average – Here’s Why

Generate Biomedicines Inc (NASDAQ:GENB)’s share price passed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $14.15 and traded as high as $15.39. Generate Biomedicines shares last traded at $15.38, with a volume of 3,927,640 shares changing hands.

Analysts Set New Price Targets

GENB has been the topic of several research reports. HC Wainwright restated a “buy” rating on shares of Generate Biomedicines in a report on Friday. Wall Street Zen cut shares of Generate Biomedicines from a “hold” rating to a “sell” rating in a research note on Saturday, October 17th. Finally, Weiss Ratings raised Generate Biomedicines from a “sell (d)” rating to a “sell (d+)” rating in a research report on Friday, September 25th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Generate Biomedicines has a consensus rating of “Moderate Buy” and a consensus price target of $26.40.

Generate Biomedicines Price Performance

The stock’s 50-day simple moving average is $15.00 and its 200 day simple moving average is $14.16.

Generate Biomedicines (NASDAQ:GENB) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.04). The business had revenue of $6.31 million during the quarter. Equities research analysts predict that Generate Biomedicines Inc will post -2.29 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Braidwell LP acquired a new stake in Generate Biomedicines during the 2nd quarter worth $55,398,000. Banque Pictet & Cie SA acquired a new stake in Generate Biomedicines during the 3rd quarter worth $26,631,000. State Street Corp acquired a new stake in Generate Biomedicines during the 2nd quarter worth $8,883,000. The Manufacturers Life Insurance Company bought a new position in Generate Biomedicines during the second quarter worth about $1,431,000. Finally, Bank Pictet & Cie Europe AG bought a new position in Generate Biomedicines during the third quarter worth about $1,168,000.

About Generate Biomedicines

Generate Biomedicines is a biotechnology company that uses generative artificial intelligence, machine learning and protein engineering to design novel protein-based medicines. Its platform is intended to identify and develop therapeutic proteins with desired biological properties, potentially shortening the time required to discover new drug candidates.

The company’s research activities focus on applying computational biology and laboratory experimentation to create medicines for a range of diseases, including conditions in immunology, inflammation, oncology and other areas of significant unmet medical need.